ZA200806937B - Combination of triazine derivatives and HMG-CoA reductase inhibitors for the treatment of diabetes - Google Patents

Combination of triazine derivatives and HMG-CoA reductase inhibitors for the treatment of diabetes

Info

Publication number
ZA200806937B
ZA200806937B ZA200806937A ZA200806937A ZA200806937B ZA 200806937 B ZA200806937 B ZA 200806937B ZA 200806937 A ZA200806937 A ZA 200806937A ZA 200806937 A ZA200806937 A ZA 200806937A ZA 200806937 B ZA200806937 B ZA 200806937B
Authority
ZA
South Africa
Prior art keywords
hmg
diabetes
treatment
combination
coa reductase
Prior art date
Application number
ZA200806937A
Other languages
English (en)
Inventor
Moinet Gerard
Cravo Daniel
Mesangeau Didier
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA200806937B publication Critical patent/ZA200806937B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
ZA200806937A 2006-01-13 2008-08-12 Combination of triazine derivatives and HMG-CoA reductase inhibitors for the treatment of diabetes ZA200806937B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0600343A FR2896158B1 (fr) 2006-01-13 2006-01-13 Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.

Publications (1)

Publication Number Publication Date
ZA200806937B true ZA200806937B (en) 2009-07-29

Family

ID=36649749

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200806937A ZA200806937B (en) 2006-01-13 2008-08-12 Combination of triazine derivatives and HMG-CoA reductase inhibitors for the treatment of diabetes

Country Status (14)

Country Link
US (1) US20100158999A1 (ko)
EP (1) EP1978951A2 (ko)
JP (1) JP2009523141A (ko)
KR (1) KR20080085208A (ko)
CN (1) CN101355935A (ko)
AR (1) AR059031A1 (ko)
AU (1) AU2006334733A1 (ko)
BR (1) BRPI0621420A2 (ko)
CA (1) CA2636840A1 (ko)
EA (1) EA200801666A1 (ko)
FR (1) FR2896158B1 (ko)
IL (1) IL192594A0 (ko)
WO (1) WO2007079916A2 (ko)
ZA (1) ZA200806937B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP5320399B2 (ja) * 2007-08-31 2013-10-23 ハナル バイオファーマ カンパニーリミテッド １，３，５−トリアジン−２，４，６−トリアミン化合物またはその薬学的に許容可能な塩と、それを含む薬学組成物
EP2367802B1 (en) 2008-12-12 2016-04-20 Poxel Tetrahydrotriazine compounds for treating diseases associated with ampk activity
FR2948028B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Association d'un inhibiteur de l'echangeur sodium-proton et d'un derive amine de dihydro-1,3,5-triazine
EP2602249B1 (en) * 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
MX2020013210A (es) 2018-06-06 2021-02-26 Metavant Sciences Gmbh Metodos de tratamiento de sujetos que padecen diabetes con enfermedad renal cronica.
EP3806828A1 (en) * 2018-06-14 2021-04-21 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
KR20220113942A (ko) * 2019-12-13 2022-08-17 스미토모 파마 가부시키가이샤 제조성 및 용출성이 우수한 소형 정제

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3651816B2 (ja) * 1995-07-03 2005-05-25 三共株式会社 動脈硬化症予防および治療剤
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin

Also Published As

Publication number Publication date
JP2009523141A (ja) 2009-06-18
WO2007079916A3 (en) 2007-12-06
EA200801666A1 (ru) 2008-12-30
FR2896158B1 (fr) 2008-09-12
BRPI0621420A2 (pt) 2011-12-06
IL192594A0 (en) 2009-09-22
CN101355935A (zh) 2009-01-28
AR059031A1 (es) 2008-03-12
AU2006334733A1 (en) 2007-07-19
KR20080085208A (ko) 2008-09-23
FR2896158A1 (fr) 2007-07-20
US20100158999A1 (en) 2010-06-24
EP1978951A2 (en) 2008-10-15
CA2636840A1 (en) 2007-07-19
WO2007079916A2 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
EP1948168A4 (en) COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND / OR HMG-COA REDUCTASE
HUS1800006I1 (hu) Alfa-MSH származékok fotodermatózisok kezelésére
ZA200806937B (en) Combination of triazine derivatives and HMG-CoA reductase inhibitors for the treatment of diabetes
HK1139036A1 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
IL198349A0 (en) Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors
AP2870A (en) Odcase inhibitors for the treatment of malaria
IL201650A0 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
EP2063897A4 (en) KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES
EP2063896A4 (en) KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES
ZA200805152B (en) Inhibitors of IAP
EP2099448A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF RESTENOSIS
EP2180891A4 (en) COMBINATION PREPARATION WITH HMG COA REDUCTASE INHIBITORS AND ASPIRIN AND METHOD FOR THE PRODUCTION THEREOF
EP1812078A4 (en) KINASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY
PL2254589T3 (pl) Związki i sposoby zapobiegania lub leczenia restenozy
SI1971330T1 (sl) Kombinacija derivatov triazina in insulinskih senzibilizatorjev
PL2410047T3 (pl) Oksydoreduktaza i jej zastosowanie do redukcji sekodionu
IL202523A0 (en) Buspirone for the treatment of mausea and vomiting
SI1937696T1 (sl) Postopek za pripravo zaviralcev HMG-CoA reduktaz
EP1812019A4 (en) COMBINATION OF POLYCHITOSAMINE AND HMG-COA REDUCTASE INHIBITOR FOR THE TREATMENT OF HYPERLIPIDEMIA
GB2416174B (en) An article for increasing titanium content of steel
EP2049102A4 (en) POLYMORPHIC FORMS OF AN HMG COA REDUCTASE HEATHER AND USE
EP1871396A4 (en) STABILIZED PHARMACEUTICAL COMPOSITIONS WITH AN HMG COA REDUCTASE INHIBITOR
HK1081843A1 (en) Pharmaceutical composition comprising reductase inhibitor hmg-coa and melatonin
ZA200802080B (en) P13K inhibitors for the treatment of endometriosis
ZA200806936B (en) Combination of triazine derivatives and pparoagonists